Extracorporeal photochemotherapy (ECP) is considered as an immune modulating therapy
majorly targeting the T cells of the Immune system. ECP induces an anti-inflammatory …

The treatment of sclerosing skin diseases [systemic sclerosis, localized scleroderma, lichen
sclerosus et atrophicus, sclerodermoid graft‐vs.‐host disease, scleredema adultorum …

The aim of our study was to assess the efficacy of extracorporeal photopheresis (ECP) in
chronic graft-versus-host disease (GVHD). Eleven patients with chronic cutaneous GVHD …

Graft-vs-host disease (GVHD) remains a major cause of morbidity and mortality after
allogeneic stem cell transplantation. GVHD was first described by Barnes and Mole1 as a …

Until recently, various therapies for localized scleroderma have been used with limited
success. Recently, phototherapy, with or without psoralen, was proposed as a successful …

Extracorporeal photopheresis (ECP) and psoralen plus ultraviolet A therapy (PUVA) are
widely accepted types of photochemotherapy used for the treatment of cutaneous T-cell …

Eight patients with progressive systemic sclerosis were treated with photopheresis or
extracorporeal photochemotherapy given on 2 consecutive days every 4 weeks for 5 to 8 …

Extracorporeal exposure of peripheral blood mononuclear cells to the photosensitizing
agent 8-methoxypsoralen and UV-A radiation has been shown to be effective in the …

Aim: The effects of low dose ultraviolet A‐1 (UVA‐1) phototherapy on different clinical stages
of morphea (localized scleroderma) were analyzed in this case study. Based on these data …

The immune system is tasked with the unique challenge of recognizing foreign pathogens
and damaged cells while at the same time preserving and protecting the integrity of “self” …